The role of academia in early drug development: from basic research to industrial translation
Article Sidebar
Publicado
ene 28, 2026
##plugins.pubIds.doi.readerDisplayName##
https://doi.org/10.30878/ces.v32n0a63
Main Article Content
Sarah Eliuth Ochoa Hugo
http://orcid.org/0000-0003-2964-4208
http://orcid.org/0000-0003-2964-4208
Resumen
Este artículo analiza el papel de la academia en el desarrollo temprano de fármacos, abarcando desde la investigación básica hasta su aplicación industrial. A partir de una búsqueda bibliográfica especializada, se describen estrategias como el cribado fenotípico, virtual y por fragmentos, el diseño racional, el modelado computacional, la predicción farmacocinética in silico y los ensayos preclínicos. Se identifican limitaciones metodológicas, falta de estandarización e insuficiente interacción con la industria, factores que dificultan el avance traslacional. Se concluye que una colaboración temprana entre academia e industria y una mejor organización del trabajo científico son esenciales para acelerar la innovación terapéutica y transformar los hallazgos en beneficios concretos para la salud pública.
Article Details
Como citar
OCHOA HUGO, Sarah Eliuth.
The role of academia in early drug development: from basic research to industrial translation.
CIENCIA ergo-sum, [S.l.], v. 33, ene. 2026.
ISSN 2395-8782.
Disponible en: <https://cienciaergosum.uaemex.mx/article/view/26042>. Fecha de acceso: 11 jun. 2026
doi: https://doi.org/10.30878/ces.v32n0a63.
Sección
Ciencias de la salud humana
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Citas
A Powerful Pairing: Academia-Industry Collaborations for Pharmaceutical Innovation. (n.d.). Retrieved May 8, 2025, from https://www.worldpharmatoday.com/articles/a-powerful-pairing-academia-industry-collaborations-for-pharmaceutical-innovation/
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Orhan, I. E., Banach, M., Rollinger, J. M.,
Atkinson, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., Hoth, D. F., Oates, J. A., Peck, C. C., Schooley, R. T., Spilker, B. A., Woodcock, J., & Zeger, S. L. (2001). Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clinical Pharmacology and Therapeutics, 69(3), 89–95. https://doi.org/10.1067/MCP.2001.113989
Barreca, D., Weckwerth, W., Bauer, R., Bayer, E. A., Majeed, M., Bishayee, A., Bochkov, V., Bonn, G. K., Braidy, N., Bucar, F., Cifuentes, A., D’Onofrio, G., Bodkin, M., Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. In Nature Reviews Drug Discovery (Vol. 20, Issue 3, pp. 200–216). Nature Research. https://doi.org/10.1038/s41573-020-00114-z
Bajorath, J. (2002). Integration of virtual and high-throughput screening. In Nature Reviews Drug Discovery (Vol. 1, Issue 11, pp. 882–894). https://doi.org/10.1038/nrd941
Barnes, E. C., Kumar, R., & Davis, R. A. (2016). The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery. Natural Product Reports, 33(3), 372–381. https://doi.org/10.1039/C5NP00121H
Beevers, C., Uno, Y., Meurer, K., Hamada, S., Hashimoto, K., Kirkland, D., LeBaron, M. J., Le Curieux, F., Le Hegarat, L., Martus, H., Masumura, K., Ohyama, W., Roberts, D. J., Vasquez, M., Whitwell, J., & Witt, K. L. (2023). In Vivo Genotoxicity Testing Strategies: Report from the 8th International Workshop on Genotoxicity Testing (IWGT). Environmental and Molecular Mutagenesis. https://doi.org/10.1002/EM.22578
BiG-SCAPE CORASON | July 2018. (n.d.). Retrieved July 18, 2023, from https://bigscape-corason.secondarymetabolites.org/index.html
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020a). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807–1821. https://doi.org/10.1016/j.drudis.2020.07.024
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020b). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807–1821. https://doi.org/10.1016/j.drudis.2020.07.024
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012). Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. In Nature Reviews Drug Discovery (Vol. 11, Issue 12, pp. 909–922). https://doi.org/10.1038/nrd3845
Caroline dos Santos Picanço, L., Ozela, P. F., de Fátima de Brito Brito, M., Pinheiro, A. A., Padilha, E. C., Braga, F. S., Henrique Tomich de Paula da Silva, C., Breno Rodrigues dos Santos, C., Rosa, J. M., & Izabel da Silva Hage-Melim, L. (2018). Alzheimer’s Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Current Medicinal Chemistry, 25, 3141–3159. https://doi.org/10.2174/09298673236661612131
ChEMBL Database. (n.d.). Retrieved November 27, 2022, from https://www.ebi.ac.uk/chembl/
Cheng, F., Ma, Y., Uzzi, B., & Loscalzo, J. (2020). Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis. BMC Biology, 18(1), 1–9. https://doi.org/10.1186/S12915-020-00868-3/TABLES/1
Cowling, B. S., & Thielemans, L. (2020). Translational medicine in neuromuscular disorders: From academia to industry. DMM Disease Models and Mechanisms, 13(2). https://doi.org/10.1242/DMM.041434/225259
Drug Central. (n.d.). Retrieved June 20, 2023, from https://drugcentral.org/
Ellinger, B., & Gribbon, P. (2016). Risk mitigation in academic drug discovery. Expert Opinion on Drug Discovery, 11(4), 333–336. https://doi.org/10.1517/17460441.2016.1152257,
Finegold, D., & Moser, A. (2006). Ethical decision-making in bioscience firms. Nat Biotechnol, 24(3), 285–290. https://doi.org/10.1038/nbt0306-285
Flobak, Å., Skånland, S. S., Hovig, E., Taskén, K., & Russnes, H. G. (2022). Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. In Trends in Pharmacological Sciences (Vol. 43, Issue 11, pp. 973–985). Elsevier Ltd. https://doi.org/10.1016/j.tips.2022.08.009
Giordano, D., Biancaniello, C., Argenio, M. A., & Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. In Pharmaceuticals (Vol. 15, Issue 5). MDPI. https://doi.org/10.3390/ph15050646
GTEx Portal. (n.d.). Retrieved June 20, 2023, from https://gtexportal.org/home/tissue/Thyroid
Health products policy and standards. (n.d.). Retrieved June 20, 2023, from https://www.who.int/teams/health-product-and-policy-standards/inn
Home | IUPHAR/BPS Guide to PHARMACOLOGY. (n.d.). Retrieved June 20, 2023, from https://www.guidetopharmacology.org/
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. Del, Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., Shorte, S. L., Turcatti, G., Von Schantz, C., & Carragher, N. O. (2016). Screening out irrelevant cell-based models of disease. In Nature Reviews Drug Discovery (Vol. 15, Issue 11, pp. 751–769). Nature Publishing Group. https://doi.org/10.1038/nrd.2016.175
IDG. (n.d.). Retrieved June 20, 2023, from https://druggablegenome.net/
Kim, S. (2016). Getting the most out of PubChem for virtual screening. In Expert Opinion on Drug Discovery (Vol. 11, Issue 9, pp. 843–855). Taylor and Francis Ltd. https://doi.org/10.1080/17460441.2016.1216967
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015a). Predicting drug metabolism: Experiment and/or computation? In Nature Reviews Drug Discovery (Vol. 14, Issue 6, pp. 387–404). Nature Publishing Group. https://doi.org/10.1038/nrd4581
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015b). Predicting drug metabolism: Experiment and/or computation? In Nature Reviews Drug Discovery (Vol. 14, Issue 6, pp. 387–404). Nature Publishing Group. https://doi.org/10.1038/nrd4581
Koçak, M., & Akçalı, Z. (2025). The published role of artificial intelligence in drug discovery and development: a bibliometric and social network analysis from 1990 to 2023. Journal of Cheminformatics 2025 17:1, 17(1), 1–24. https://doi.org/10.1186/S13321-025-00988-4
Kraus, V. B. (2018). Biomarkers as drug development tools: discovery, validation, qualification and use. Nature Reviews. Rheumatology, 14(6), 354–362. https://doi.org/10.1038/S41584-018-0005-9
Langer, T., & Hoffmann, R. D. (2006). Pharmacophores and Pharmacophore Searches. Pharmacophores and Pharmacophore Searches, 1–375. https://doi.org/10.1002/3527609164
Learn About Studies | ClinicalTrials.gov. (n.d.). Retrieved November 14, 2023, from https://clinicaltrials.gov/study-basics/learn-about-studies#q2
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation | Eli Lilly and Company. (n.d.). Retrieved May 8, 2025, from https://investor.lilly.com/news-releases/news-release-details/lilly-plans-expand-purdue-university-collaboration-250-million
Liotta, D., & Painter, G. (2018). Academic Drug Development: The DRIVE Model. ACS Medicinal Chemistry Letters, 9(5), 403–407. https://doi.org/10.1021/ACSMEDCHEMLETT.8B00124,
Lipinski, C. A. (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. In Advanced Drug Delivery Reviews (Vol. 101, pp. 34–41). Elsevier B.V. https://doi.org/10.1016/j.addr.2016.04.029
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. In Advanced Drug Delivery Reviews (Vol. 64, Issue SUPPL., pp. 4–17). https://doi.org/10.1016/j.addr.2012.09.019
Liu, M., & Quinn, R. J. (2019). Fragment-based screening with natural products for novel anti-parasitic disease drug discovery. In Expert Opinion on Drug Discovery (Vol. 14, Issue 12, pp. 1283–1295). Taylor and Francis Ltd. https://doi.org/10.1080/17460441.2019.1653849
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., Shoichet, B. K., & Urban, L. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature, 486(7403), 361–367. https://doi.org/10.1038/nature11159
Mackie, J. E., Taylor, A. D., Finegold, D. L., Daar, A. S., & Singer, P. A. (2006). Lessons on ethical decision making from the bioscience industry. PLoS Med, 3(5), e129. https://doi.org/10.1371/journal.pmed.0030129
Mayr, L. M., & Bojanic, D. (2009). Novel trends in high-throughput screening. In Current Opinion in Pharmacology (Vol. 9, Issue 5, pp. 580–588). https://doi.org/10.1016/j.coph.2009.08.004
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., Gordillo-Marañón, M., Hunter, F., Junco, L., Mugumbate, G., Rodriguez-Lopez, M., Atkinson, F., Bosc, N., Radoux, C. J., Segura-Cabrera, A., Leach, A. R. (2019). ChEMBL: Towards direct deposition of bioassay data. Nucleic Acids Research, 47(D1), D930–D940. https://doi.org/10.1093/nar/gky1075
Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. In Nature Reviews Drug Discovery (Vol. 13, Issue 9, pp. 655–672). Nature Publishing Group. https://doi.org/10.1038/nrd4363
Mitsopoulos, C., Di Micco, P., Fernandez, E. V., Dolciami, D., Holt, E., Mica, I. L., Coker, E. A., Tym, J. E., Campbell, J., Che, K. H., Ozer, B., Kannas, C., Antolin, A. A., Workman, P., & Al-Lazikani, B. (2021). CanSAR: Update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 49(D1), D1074–D1082. https://doi.org/10.1093/NAR/GKAA1059
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017). Opportunities and challenges in phenotypic drug discovery: An industry perspective. In Nature Reviews Drug Discovery (Vol. 16, Issue 8). https://doi.org/10.1038/nrd.2017.111
Muller, P. Y., & Milton, M. N. (2012). The determination and interpretation of the therapeutic index in drug development. In Nature Reviews Drug Discovery (Vol. 11, Issue 10, pp. 751–761). https://doi.org/10.1038/nrd3801
NCATS Pharmaceutical Collection | National Center for Advancing Translational Sciences. (n.d.). Retrieved June 20, 2023, from https://ncats.nih.gov/expertise/preclinical/npc
Nussbaumer, P., & Klebl, B. (2015). Professional translational research: A new hybrid paradigm in early drug discovery. Future Medicinal Chemistry, 7(14), 1879–1889. https://doi.org/10.4155/FMC.15.124;REQUESTEDJOURNAL:JOURNAL:IFMC20;WGROUP:STRING:PUBLICATION
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025). Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomarker Research, 13(1), 1–12. https://doi.org/10.1186/S40364-025-00758-2;TYPE=ARTICLE;KWRD=ARTIFICIAL
Ohlson, S., & Duong-Thi, M. D. (2018). Fragment screening for drug leads by weak affinity chromatography (WAC-MS). In Methods (Vol. 146, pp. 26–38). Academic Press Inc. https://doi.org/10.1016/j.ymeth.2018.01.011
Passini, E., Zhou, X., Trovato, C., Britton, O. J., Bueno-Orovio, A., & Rodriguez, B. (2021). The virtual assay software for human in silico drug trials to augment drug cardiac testing. Journal of Computational Science, 52. https://doi.org/10.1016/j.jocs.2020.101202
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013). Validating therapeutic targets through human genetics. In Nature Reviews Drug Discovery (Vol. 12, Issue 8, pp. 581–594). https://doi.org/10.1038/nrd4051
Prinz, F., Schlange, T., & Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews. Drug Discovery, 10(9), 712–713. https://doi.org/10.1038/NRD3439-C1
PubMed. (n.d.). Retrieved November 27, 2022, from https://pubmed.ncbi.nlm.nih.gov/
Ramadan, Q., Perinelli, D. R., Orian, L., & Baratchi, S. (2023). Editorial: Innovative approaches in drug discovery and development. Frontiers in Medical Technology, 5, 1206088. https://doi.org/10.3389/FMEDT.2023.1206088/BIBTEX
Seidel, T., Wieder, O., Garon, A., & Langer, T. (2020). Applications of the Pharmacophore Concept in Natural Product inspired Drug Design. In Molecular Informatics (Vol. 39, Issue 11). Wiley-VCH Verlag. https://doi.org/10.1002/minf.202000059
Shamoo, A. E., & Resnik, D. B. (2022b). Collaboration within Academia and with Industry. Responsible Conduct of Research, 83–105. https://doi.org/10.1093/OSO/9780197547090.003.0004
The Collaboration Between Industry and Academia in Drug Development. (n.d.). Retrieved May 8, 2025, from https://blog.drugbank.com/the-collaboration-between-industry-and-academia-in-drug-development/
The Role of Artificial Intelligence in Drug Discovery. (n.d.). Retrieved May 8, 2025, from https://natlawreview.com/article/unlocking-future-medicine-role-ai-drug-discovery
Tong, H., Phan, N. V. T., Nguyen, T. T., Nguyen, D. V., Vo, N. S., & Le, L. (2021). Review on databases and bioinformatic approaches on pharmacogenomics of adverse drug reactions. In Pharmacogenomics and Personalized Medicine (Vol. 14, pp. 61–75). Dove Medical Press Ltd. https://doi.org/10.2147/PGPM.S290781
Van Campen, L. E., Poplazarova, T., Therasse, D. G., Turik, M., Kelman, A., Rossetti, A., Chang, C., Stern, K. N., & Fortson, W. (2021). Considerations for applying bioethics norms to a biopharmaceutical industry setting. BMC Medical Ethics, 22(1), 1–11. https://doi.org/10.1186/S12910-021-00600-Y/FIGURES/2
Whitebread, S., Dumotier, B., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urban, L. (2016). Secondary pharmacology: screening and interpretation of off-target activities – focus on translation. In Drug Discovery Today (Vol. 21, Issue 8, pp. 1232–1242). Elsevier Ltd. https://doi.org/10.1016/j.drudis.2016.04.021
WHOCC - ATC/DDD Index. (n.d.). Retrieved June 20, 2023, from https://www.whocc.no/atc_ddd_index/
Willett, P. (2006). Similarity-based virtual screening using 2D fingerprints. In Drug Discovery Today (Vol. 11, Issues 23–24, pp. 1046–1053). https://doi.org/10.1016/j.drudis.2006.10.005
Yu, B., Lu, X., & Chang, J. (2024). Multidisciplinary Training for Fostering Next-Generation Medicinal Chemists. Journal of Medicinal Chemistry. https://doi.org/10.1021/ACS.JMEDCHEM.4C02316;REQUESTEDJOURNAL:JOURNAL:JMCMAR;JOURNAL:JOURNAL:JMCMAR;PAGE:STRING:ARTICLE/CHAPTER
Zhang, J. H., Chung, T. D. Y., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4(2). https://doi.org/10.1177/108705719900400206
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Orhan, I. E., Banach, M., Rollinger, J. M.,
Atkinson, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., Hoth, D. F., Oates, J. A., Peck, C. C., Schooley, R. T., Spilker, B. A., Woodcock, J., & Zeger, S. L. (2001). Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clinical Pharmacology and Therapeutics, 69(3), 89–95. https://doi.org/10.1067/MCP.2001.113989
Barreca, D., Weckwerth, W., Bauer, R., Bayer, E. A., Majeed, M., Bishayee, A., Bochkov, V., Bonn, G. K., Braidy, N., Bucar, F., Cifuentes, A., D’Onofrio, G., Bodkin, M., Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. In Nature Reviews Drug Discovery (Vol. 20, Issue 3, pp. 200–216). Nature Research. https://doi.org/10.1038/s41573-020-00114-z
Bajorath, J. (2002). Integration of virtual and high-throughput screening. In Nature Reviews Drug Discovery (Vol. 1, Issue 11, pp. 882–894). https://doi.org/10.1038/nrd941
Barnes, E. C., Kumar, R., & Davis, R. A. (2016). The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery. Natural Product Reports, 33(3), 372–381. https://doi.org/10.1039/C5NP00121H
Beevers, C., Uno, Y., Meurer, K., Hamada, S., Hashimoto, K., Kirkland, D., LeBaron, M. J., Le Curieux, F., Le Hegarat, L., Martus, H., Masumura, K., Ohyama, W., Roberts, D. J., Vasquez, M., Whitwell, J., & Witt, K. L. (2023). In Vivo Genotoxicity Testing Strategies: Report from the 8th International Workshop on Genotoxicity Testing (IWGT). Environmental and Molecular Mutagenesis. https://doi.org/10.1002/EM.22578
BiG-SCAPE CORASON | July 2018. (n.d.). Retrieved July 18, 2023, from https://bigscape-corason.secondarymetabolites.org/index.html
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020a). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807–1821. https://doi.org/10.1016/j.drudis.2020.07.024
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020b). High-Throughput Screening: today’s biochemical and cell-based approaches. Drug Discovery Today, 25(10), 1807–1821. https://doi.org/10.1016/j.drudis.2020.07.024
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012). Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. In Nature Reviews Drug Discovery (Vol. 11, Issue 12, pp. 909–922). https://doi.org/10.1038/nrd3845
Caroline dos Santos Picanço, L., Ozela, P. F., de Fátima de Brito Brito, M., Pinheiro, A. A., Padilha, E. C., Braga, F. S., Henrique Tomich de Paula da Silva, C., Breno Rodrigues dos Santos, C., Rosa, J. M., & Izabel da Silva Hage-Melim, L. (2018). Alzheimer’s Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Current Medicinal Chemistry, 25, 3141–3159. https://doi.org/10.2174/09298673236661612131
ChEMBL Database. (n.d.). Retrieved November 27, 2022, from https://www.ebi.ac.uk/chembl/
Cheng, F., Ma, Y., Uzzi, B., & Loscalzo, J. (2020). Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis. BMC Biology, 18(1), 1–9. https://doi.org/10.1186/S12915-020-00868-3/TABLES/1
Cowling, B. S., & Thielemans, L. (2020). Translational medicine in neuromuscular disorders: From academia to industry. DMM Disease Models and Mechanisms, 13(2). https://doi.org/10.1242/DMM.041434/225259
Drug Central. (n.d.). Retrieved June 20, 2023, from https://drugcentral.org/
Ellinger, B., & Gribbon, P. (2016). Risk mitigation in academic drug discovery. Expert Opinion on Drug Discovery, 11(4), 333–336. https://doi.org/10.1517/17460441.2016.1152257,
Finegold, D., & Moser, A. (2006). Ethical decision-making in bioscience firms. Nat Biotechnol, 24(3), 285–290. https://doi.org/10.1038/nbt0306-285
Flobak, Å., Skånland, S. S., Hovig, E., Taskén, K., & Russnes, H. G. (2022). Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. In Trends in Pharmacological Sciences (Vol. 43, Issue 11, pp. 973–985). Elsevier Ltd. https://doi.org/10.1016/j.tips.2022.08.009
Giordano, D., Biancaniello, C., Argenio, M. A., & Facchiano, A. (2022). Drug Design by Pharmacophore and Virtual Screening Approach. In Pharmaceuticals (Vol. 15, Issue 5). MDPI. https://doi.org/10.3390/ph15050646
GTEx Portal. (n.d.). Retrieved June 20, 2023, from https://gtexportal.org/home/tissue/Thyroid
Health products policy and standards. (n.d.). Retrieved June 20, 2023, from https://www.who.int/teams/health-product-and-policy-standards/inn
Home | IUPHAR/BPS Guide to PHARMACOLOGY. (n.d.). Retrieved June 20, 2023, from https://www.guidetopharmacology.org/
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. Del, Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., Shorte, S. L., Turcatti, G., Von Schantz, C., & Carragher, N. O. (2016). Screening out irrelevant cell-based models of disease. In Nature Reviews Drug Discovery (Vol. 15, Issue 11, pp. 751–769). Nature Publishing Group. https://doi.org/10.1038/nrd.2016.175
IDG. (n.d.). Retrieved June 20, 2023, from https://druggablegenome.net/
Kim, S. (2016). Getting the most out of PubChem for virtual screening. In Expert Opinion on Drug Discovery (Vol. 11, Issue 9, pp. 843–855). Taylor and Francis Ltd. https://doi.org/10.1080/17460441.2016.1216967
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015a). Predicting drug metabolism: Experiment and/or computation? In Nature Reviews Drug Discovery (Vol. 14, Issue 6, pp. 387–404). Nature Publishing Group. https://doi.org/10.1038/nrd4581
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015b). Predicting drug metabolism: Experiment and/or computation? In Nature Reviews Drug Discovery (Vol. 14, Issue 6, pp. 387–404). Nature Publishing Group. https://doi.org/10.1038/nrd4581
Koçak, M., & Akçalı, Z. (2025). The published role of artificial intelligence in drug discovery and development: a bibliometric and social network analysis from 1990 to 2023. Journal of Cheminformatics 2025 17:1, 17(1), 1–24. https://doi.org/10.1186/S13321-025-00988-4
Kraus, V. B. (2018). Biomarkers as drug development tools: discovery, validation, qualification and use. Nature Reviews. Rheumatology, 14(6), 354–362. https://doi.org/10.1038/S41584-018-0005-9
Langer, T., & Hoffmann, R. D. (2006). Pharmacophores and Pharmacophore Searches. Pharmacophores and Pharmacophore Searches, 1–375. https://doi.org/10.1002/3527609164
Learn About Studies | ClinicalTrials.gov. (n.d.). Retrieved November 14, 2023, from https://clinicaltrials.gov/study-basics/learn-about-studies#q2
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation | Eli Lilly and Company. (n.d.). Retrieved May 8, 2025, from https://investor.lilly.com/news-releases/news-release-details/lilly-plans-expand-purdue-university-collaboration-250-million
Liotta, D., & Painter, G. (2018). Academic Drug Development: The DRIVE Model. ACS Medicinal Chemistry Letters, 9(5), 403–407. https://doi.org/10.1021/ACSMEDCHEMLETT.8B00124,
Lipinski, C. A. (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. In Advanced Drug Delivery Reviews (Vol. 101, pp. 34–41). Elsevier B.V. https://doi.org/10.1016/j.addr.2016.04.029
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. In Advanced Drug Delivery Reviews (Vol. 64, Issue SUPPL., pp. 4–17). https://doi.org/10.1016/j.addr.2012.09.019
Liu, M., & Quinn, R. J. (2019). Fragment-based screening with natural products for novel anti-parasitic disease drug discovery. In Expert Opinion on Drug Discovery (Vol. 14, Issue 12, pp. 1283–1295). Taylor and Francis Ltd. https://doi.org/10.1080/17460441.2019.1653849
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., Shoichet, B. K., & Urban, L. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature, 486(7403), 361–367. https://doi.org/10.1038/nature11159
Mackie, J. E., Taylor, A. D., Finegold, D. L., Daar, A. S., & Singer, P. A. (2006). Lessons on ethical decision making from the bioscience industry. PLoS Med, 3(5), e129. https://doi.org/10.1371/journal.pmed.0030129
Mayr, L. M., & Bojanic, D. (2009). Novel trends in high-throughput screening. In Current Opinion in Pharmacology (Vol. 9, Issue 5, pp. 580–588). https://doi.org/10.1016/j.coph.2009.08.004
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., Gordillo-Marañón, M., Hunter, F., Junco, L., Mugumbate, G., Rodriguez-Lopez, M., Atkinson, F., Bosc, N., Radoux, C. J., Segura-Cabrera, A., Leach, A. R. (2019). ChEMBL: Towards direct deposition of bioassay data. Nucleic Acids Research, 47(D1), D930–D940. https://doi.org/10.1093/nar/gky1075
Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. In Nature Reviews Drug Discovery (Vol. 13, Issue 9, pp. 655–672). Nature Publishing Group. https://doi.org/10.1038/nrd4363
Mitsopoulos, C., Di Micco, P., Fernandez, E. V., Dolciami, D., Holt, E., Mica, I. L., Coker, E. A., Tym, J. E., Campbell, J., Che, K. H., Ozer, B., Kannas, C., Antolin, A. A., Workman, P., & Al-Lazikani, B. (2021). CanSAR: Update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 49(D1), D1074–D1082. https://doi.org/10.1093/NAR/GKAA1059
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017). Opportunities and challenges in phenotypic drug discovery: An industry perspective. In Nature Reviews Drug Discovery (Vol. 16, Issue 8). https://doi.org/10.1038/nrd.2017.111
Muller, P. Y., & Milton, M. N. (2012). The determination and interpretation of the therapeutic index in drug development. In Nature Reviews Drug Discovery (Vol. 11, Issue 10, pp. 751–761). https://doi.org/10.1038/nrd3801
NCATS Pharmaceutical Collection | National Center for Advancing Translational Sciences. (n.d.). Retrieved June 20, 2023, from https://ncats.nih.gov/expertise/preclinical/npc
Nussbaumer, P., & Klebl, B. (2015). Professional translational research: A new hybrid paradigm in early drug discovery. Future Medicinal Chemistry, 7(14), 1879–1889. https://doi.org/10.4155/FMC.15.124;REQUESTEDJOURNAL:JOURNAL:IFMC20;WGROUP:STRING:PUBLICATION
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025). Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomarker Research, 13(1), 1–12. https://doi.org/10.1186/S40364-025-00758-2;TYPE=ARTICLE;KWRD=ARTIFICIAL
Ohlson, S., & Duong-Thi, M. D. (2018). Fragment screening for drug leads by weak affinity chromatography (WAC-MS). In Methods (Vol. 146, pp. 26–38). Academic Press Inc. https://doi.org/10.1016/j.ymeth.2018.01.011
Passini, E., Zhou, X., Trovato, C., Britton, O. J., Bueno-Orovio, A., & Rodriguez, B. (2021). The virtual assay software for human in silico drug trials to augment drug cardiac testing. Journal of Computational Science, 52. https://doi.org/10.1016/j.jocs.2020.101202
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013). Validating therapeutic targets through human genetics. In Nature Reviews Drug Discovery (Vol. 12, Issue 8, pp. 581–594). https://doi.org/10.1038/nrd4051
Prinz, F., Schlange, T., & Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews. Drug Discovery, 10(9), 712–713. https://doi.org/10.1038/NRD3439-C1
PubMed. (n.d.). Retrieved November 27, 2022, from https://pubmed.ncbi.nlm.nih.gov/
Ramadan, Q., Perinelli, D. R., Orian, L., & Baratchi, S. (2023). Editorial: Innovative approaches in drug discovery and development. Frontiers in Medical Technology, 5, 1206088. https://doi.org/10.3389/FMEDT.2023.1206088/BIBTEX
Seidel, T., Wieder, O., Garon, A., & Langer, T. (2020). Applications of the Pharmacophore Concept in Natural Product inspired Drug Design. In Molecular Informatics (Vol. 39, Issue 11). Wiley-VCH Verlag. https://doi.org/10.1002/minf.202000059
Shamoo, A. E., & Resnik, D. B. (2022b). Collaboration within Academia and with Industry. Responsible Conduct of Research, 83–105. https://doi.org/10.1093/OSO/9780197547090.003.0004
The Collaboration Between Industry and Academia in Drug Development. (n.d.). Retrieved May 8, 2025, from https://blog.drugbank.com/the-collaboration-between-industry-and-academia-in-drug-development/
The Role of Artificial Intelligence in Drug Discovery. (n.d.). Retrieved May 8, 2025, from https://natlawreview.com/article/unlocking-future-medicine-role-ai-drug-discovery
Tong, H., Phan, N. V. T., Nguyen, T. T., Nguyen, D. V., Vo, N. S., & Le, L. (2021). Review on databases and bioinformatic approaches on pharmacogenomics of adverse drug reactions. In Pharmacogenomics and Personalized Medicine (Vol. 14, pp. 61–75). Dove Medical Press Ltd. https://doi.org/10.2147/PGPM.S290781
Van Campen, L. E., Poplazarova, T., Therasse, D. G., Turik, M., Kelman, A., Rossetti, A., Chang, C., Stern, K. N., & Fortson, W. (2021). Considerations for applying bioethics norms to a biopharmaceutical industry setting. BMC Medical Ethics, 22(1), 1–11. https://doi.org/10.1186/S12910-021-00600-Y/FIGURES/2
Whitebread, S., Dumotier, B., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urban, L. (2016). Secondary pharmacology: screening and interpretation of off-target activities – focus on translation. In Drug Discovery Today (Vol. 21, Issue 8, pp. 1232–1242). Elsevier Ltd. https://doi.org/10.1016/j.drudis.2016.04.021
WHOCC - ATC/DDD Index. (n.d.). Retrieved June 20, 2023, from https://www.whocc.no/atc_ddd_index/
Willett, P. (2006). Similarity-based virtual screening using 2D fingerprints. In Drug Discovery Today (Vol. 11, Issues 23–24, pp. 1046–1053). https://doi.org/10.1016/j.drudis.2006.10.005
Yu, B., Lu, X., & Chang, J. (2024). Multidisciplinary Training for Fostering Next-Generation Medicinal Chemists. Journal of Medicinal Chemistry. https://doi.org/10.1021/ACS.JMEDCHEM.4C02316;REQUESTEDJOURNAL:JOURNAL:JMCMAR;JOURNAL:JOURNAL:JMCMAR;PAGE:STRING:ARTICLE/CHAPTER
Zhang, J. H., Chung, T. D. Y., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4(2). https://doi.org/10.1177/108705719900400206